

ASX RELEASE 9 November 2021

**ASX: NVU** 

## Strategic License and Supply Agreement with Cupron, Inc.

The agreement will enhance product and customer growth prospects

## **Highlights**

- Cupron will supply proprietary Cupron materials to Nanoveu for production of Nanoshield range of self-disinfecting products
- Cupron has received an Environmental Protection Authority ("EPA") Registration allowing Nanoveu to sell its Nanoshield product (using CEP) under Cupron's EPA Registration in the United States
- The Agreement follows an MOU signed on 6 May 2021, for Nanoshield Films, which has now been expanded to include Sprays, Masterbatch, and other products in development.
- The active ingredient will be used in new range of Nanoshield<sup>™</sup> MasterBatch and Spray products
- Nanoveu believes that the Agreement has significant potential based on the large addressable global market for products with the proven efficacy and US EPA registration

Nanoveu Limited ("Nanoveu" or the "Company") (ASX: NVU) is pleased to announce that it has entered into a non-exclusive License and Supply Agreement ("Agreement") with Cupron, Inc. ("Cupron"), a company incorporated in the United States focused on copper-based antimicrobial technology that harnesses the unique properties of copper for healthcare, consumer, industrial, and military applications.

Under the Agreement, Cupron will non-exclusively supply Nanoveu with proprietary Cupron materials, including copper iodide metal powder ("Cupron Enhanced Product" or "CEP") for use in the Nanoshield antiviral and antimicrobial products.

The Agreement formalises the MOU signed on 6 May 2021 (see ASX Announcement of 6 May 2021) into a binding agreement.

The Nanoshield<sup>™</sup> product is capable of using Cupron's CEP without affecting efficacy or production profile and importantly, the CEP material is registered under the United States Environmental Protection Agency (EPA), with the Agreement allowing Nanoveu to sell its Nanoshield product (using CEP) under Cupron's EPA Registration.



The Agreement will also enable Nanoveu to introduce complementary products to its Nanoshield<sup>TM</sup> film portfolio, with its antiviral technology independently demonstrated to be a highly effective agent for the inactivation of viruses and bacteria and referenced in peer reviewed reports in the American Journal of Microbiology<sup>1</sup>. The technology has been proven to eliminate 99.99% of SARS-CoV-2 (COVID-19) and HCoV-299E, OC43, another coronavirus affecting humans in 30 minutes<sup>2</sup>.

Under the Agreement, Nanoveu will be offered a fixed price for CEP material with Cupron receiving a sales royalty on US-based Nanoshield sales of 8% for the first US\$1 million sales, 6% for US\$1-10 million in sales and 4% of all sales thereafter.

The Agreement is until 31 December 2022, and thereafter the parties may extend the Agreement for a mutually agreed term.

Commenting on the Agreement Nanoveu's Non-Executive Chairman, Scott Beeton, said: "As the world adapts to the new normal from the COVID-19 pandemic, it is more important than ever before that public spaces are properly sanitised to a high standard. The ability to verify effective surface sanitisation, made possible by Nanoshield $^{TM}$ , will provide additional peace of mind to consumers.

"The Nanoshield products can be used across a large addressable global market, including public transport providers, hospitals and healthcare facilities, as well as hotels, universities and sporting venues. Nanoveu believes that the agreement has significant potential and the Board believes it will increase our value proposition even further."

- Ends -

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Scott Beeton Executive Chairman t: +65 6557 0155

e: info@nanoveu.com

For media / investor enquiries, please contact:

Jane Morgan Investor Relations

t: 0405 555 618

e: jm@janemorganmanagement.com.au

<sup>&</sup>lt;sup>1</sup> See ASX Announcement of 28 July 2021 for the testing performed and the results.

<sup>&</sup>lt;sup>2</sup> See ASX Announcements of 15 April 2020, 5 May 2020, 25 May 2020, 18 February 2021 and 28 July 2021 for the testing performed and the results.



## **About Nanoveu Limited**

We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. https://www.nanoveu.com/

**Nanoshield** - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

**EyeFly3D** - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

**Customskins -** are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

**EyeFyx -** currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.

## **About Cupron, Inc.**

Cupron, Inc. is a copper-based antimicrobial technology company that harnesses the unique properties of copper for healthcare, consumer, industrial, and military applications. Cupron embeds specified copper compounds in select polymers that enable finished products to deliver the desired impact. Unlike topically-applied solutions, Cupron's durable embedded copper technology does not wash or rub off.

Cupron's patented and proprietary embedded copper technology has earned multiple, unique public health claims from the US Environmental Protection Agency (EPA), and additional innovations are in development.